ByteDance’s drug unit presents AI-designed therapies at global conferences
SCMP Tech / 5/2/2026
📰 NewsSignals & Early TrendsIndustry & Market MovesModels & Research
Key Points
- ByteDance is expanding its use of AI in healthcare through Anew Labs, a drug-discovery unit that is presenting AI-designed therapies at international conferences.
- The organization, also referred to as Anew Therapeutics or ByteDance AI Drug Discovery, operates across Shanghai, Singapore, and San Jose.
- Its presence in global conferences highlights a push to translate AI-driven drug discovery frameworks and therapies into broader scientific and business visibility.
- The unit’s official materials list a core team and notable scientists on its scientific advisory board, signaling an effort to combine AI development with established life-science expertise.
ByteDance, the Chinese owner of TikTok, is pushing deeper into artificial intelligence with Anew Labs, a drug-discovery unit that has begun presenting its AI-designed therapies at international conferences.
The unit – also known as Anew Therapeutics or ByteDance AI Drug Discovery – operates from Shanghai, Singapore and San Jose, California.
Its official website listed 36 core members, as well as big names on its “scientific advisory board”: Liu Yongjun, former president of Innovent Biologics, Ji...
Continue reading this article on the original site.
Read original →💡 Insights using this article
This article is featured in our daily AI news digest — key takeaways and action items at a glance.
